Updates in Therapeutic Approaches to PBC Following Elafibranor Approval

In this segment of our HCPLive Special Report on Updates and Unmet Needs in PBC, Palak Trivedi, MD, PhD, and James Boyer, MD, focus their discussion on recent therapeutic advancements in primary biliary cholangitis (PBC), particularly the approval of new treatments like elafibranor and the anticipated approval of seladelpar. When prompted, Boyer provides a historical context, noting that the standard of care was previously ursodeoxycholic acid, with a significant portion of patients not responding adequately. He outlines the progression to obeticholic acid, its limitations, and the need for new therapies.

The conversation then highlights the efficacy of elafibranor and seladelpar, both of which have shown promising results in clinical trials. Boyer explains the importance of achieving significant reductions in alkaline phosphatase levels, a key prognostic marker, and the challenges of side effects like pruritus with existing therapies. The discussion underscores the potential of these new treatments to improve patient outcomes and quality of life.

Check out the other segments in this series:

• Part 1: Advances in Diagnostic Criteria and Methods for Early Detection of PBC
• Part 2: Updates in Therapeutic Approaches to PBC Following Elafibranor Approval
• Part 3: Clinical and Patient Perspectives on Unmet Needs in PBC Management
• Part 4: Beyond Current Standards: Emerging Therapies for Primary Biliary Cholangitis
• Part 5: Improving Strategies for Management of Primary Biliary Cholangitis

Subject Matter Experts:

• James Boyer, MD, Ensign Professor of Medicine at Yale School of Medicine and the Founder and Emeritus Director of the Yale Liver Center.
• Palak Trivedi, MD, PhD, Associate Professor and Honorary Consultant Hepatologist and Clinical Research Director for Industry Engagement at the University of Birmingham. Also serves as an investigator on the open-label ASSURE trial of seladelpar in patients with PBC.